Narrow-Spectrum ß-Lactam Monotherapy in Hospital Treatment of Community-Acquired Pneumonia - A Register Based Cohort Study.
Clin Microbiol Infect. 2016 Dec 22;:
Authors: Rhedin S, Galanis I, Granath F, Ternhag A, Hedlund J, Spindler C, Naucler P
OBJECTIVES: To assess the clinical effect of empirical treatment with narrow-spectrum ß-lactam monotherapy (NSBM) versus broad-spectrum ß-lactam monotherapy (BSBM) in non-severe community-acquired pneumonia (CAP).
METHODS: Hospitalised patients ≥18 years with CAP that received initial NSBM or BSBM, with a severity score according to CRB-65≤2 (C=confusion, R=respiratory rate >30/min, B=systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg, 65= ≥65 years), in the Swedish Pneumonia Register from 2008-11 were included. Primary outcome was 30-day mortality. Secondary outcomes were 90-day mortality, treatment at intensive care unit (ICU) and length of stay (LOS). Propensity score matching was performed to account for differences in baseline characteristics.
RESULTS: There were 5961 patients with CRB-65≤1 and 1344 patients with CRB-65=2. In the propensity score matched cohorts the 30-day mortality was 40/1827 (2.2%) with NSBM and 56/1827 (3.1%) with BSBM in CRB-65≤1, and 57/524 (10.9%) and 51/524 (9.7%) respectively in CRB-65=2. No significant differences in 30-day mortality were observed between NSBM and BSBM in patients with CRB-65≤1 or CRB-65=2, odds ratios: 1.41 (95% CI: 0.94-2.14) and 0.88 (95% CI: 0.59-1.32), respectively. There was no significant difference in 90-day mortality. Patients that received BSBM were more often treated at ICU and had longer LOS.
CONCLUSIONS: Empirical NSBM appears to be effective in the majority of hospitalized immunocompetent adults with non-severe CAP and should be further evaluated in randomized trials.
PMID: 28017793 [PubMed - as supplied by publisher]